Medidata launches Rave Lite for Phase I and IV trials
Medidata has launched a “lite” version of its electronic data capture (EDC) technology designed for both Phase I trials and post-approval studies.
In addition to data capture, the product – called Rave Lite – also provides analysis capabilities and is available through a “tailored price model,” which details were not provided.
Medidata chief technology officer Tom Doyle said, “Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform.
“By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions,” he said.
Medidata cited observations about access to EDC technology as a development driver, arguing that “the lack of access to innovative technology disproportionately affects early- and late-stage studies.”
Medidata claims its technologies have been used in more than 34,000 clinical trials by biopharmaceutical companies of every size. In February, French drug company Sanofi adopted an electronic clinical outcome assessment system.
Also in February, Medidata announced it had renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific.
More recently, Brazilian clinical research organization (CRO) Intrials said it would use Medidata’s CTMS, trial master file, and site payment systems in recruitment and clinical research across Latin America.
And just last month, Medidata and the European Organisation for Research and Treatment of Cancer (EORTC) announced a four-year extended partnership that sees the latter organization’s use 13 of the tech firm’s systems.
The Rave Lite launch follows Medidata’s roll out of its Clinical Data Studio announced in June. At the time the firm said the aim was to provide stakeholders with greater control over the quality of data and the ability to deliver safer trials to patients faster.
DepositPhotos/ilterriorm